Clinical Trials

13 enrolled

Leukemia

NCT03164057 2026-01-28

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

206 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

16 enrolled

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT05038592 2026-01-21

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

64 enrolled

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT03875287 2026-01-12

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

35 enrolled

Other solid neoplasm

Solid Tumor

NCT04874480 2026-01-09

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

9 enrolled

Phase 1/2 Active not recruiting

Leukemia

NCT05089370 2025-12-08

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

8 enrolled

Dermatologic

Melanoma

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

6 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04188405 2025-11-20

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

20 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT03132454 2025-11-03

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

LymphoidOther hematologic neoplasm

32 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02957968 2025-08-28

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

46 enrolled 21 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03240211 2025-08-26

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

37 enrolled

Lymphoid

Lymphoma, T-Cell

NCT04980404 2025-07-20

Inqovi Maintenance Therapy in Myeloid Neoplasms

22 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT03009240 2025-06-17

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

30 enrolled

Leukemia, Myeloid, Acute

NCT05222984 2025-05-30

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

17 enrolled

Leukemia, Myeloid, Acute

NCT03017131 2025-03-28

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1/2 Active not recruiting

9 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02204085 2025-01-24

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

33 enrolled

Leukemia, Myeloid, Acute

NCT04476199 2025-01-06

Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT

100 enrolled